美股A股
StockGist

Encompass Health Corporation

EHCNYSE · Healthcare · Medical - Care Facilities
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States.
$140.99+0.11%
报价 2026-11-13
市值
$13.83B
EV
$16.68B
PE (TTM)
22.0x
预期 PE (FY2026)
22.5x
52 周区间距高点 -1.1%
$93.83$142.51

筛选结果

pipeline · 2026-11-13
Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool

爆发潜力

2026-11-13
未命中✗ 收入线✗ EPS 线
财年收入倍数EPSPE
FY+22027-121.1x6.13 → 6.89(1.1x)20.5
FY+32028-121.2x6.13 → 7.58(1.2x)18.6

毛利率 39% · TTM 收入 $6338M · 基数 EPS 6.13(调整后)

电话会信号

辅助标签
Q3 20262026-10-29
扩产上调指引供不应求
指引 上调
信心 4
分析师 4

“We think we can get to the top of that range and potentially in the outer years, be above that range.”

原文引用(3)
  • 扩产:We continue to invest in capacity additions to help address this underserved market.
  • 上调指引:we are again raising our guidance for 2026
  • 供不应求:hospitals that have been running at greater than 90% capacity with an average occupancy of 95%

蓝色标签在暴涨研究中略有区分度;悬停查看口径。

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
EHCEncompass Health Corporation$13.83B+0.1%+9.1%21.6%22.0x10.7x30.5x
SOLVSolventum Corporation$15.14B+0.3%-0.0%53.5%7.3x5.5x–
ICLRICON Public Limited Company$14.58B-2.9%+1.6%19.6%34.7x13.4x12.2x
ELANElanco Animal Health Incorporated$13.39B+1.1%+11.2%56.9%–24.3x32.4xGARP
RDYDr. Reddy's Laboratories Limited$12.29B+0.1%–55.2%18.5x12.5x–
ALGNAlign Technology, Inc.$11.86B+0.8%+2.6%68.7%25.0x14.9x20.1x
FMSFresenius Medical Care AG & Co. KGaA$11.78B+2.0%–25.6%11.0x6.1x–Cheap
ENSGThe Ensign Group, Inc.$10.99B+1.0%+16.7%16.6%26.4x19.5x24.1x
DVADaVita Inc.$10.98B+0.3%+4.9%30.9%17.5x9.3x8.5x
同行中位数––+3.7%42.2%18.5x12.9x20.1x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

Metric
2026-09-30
Q3 2026
2026-06-30
Q2 2026
2026-03-31
Q1 2026
2025-12-31
Q4 2025
2025-09-30
Q3 2025
2025-06-30
Q2 2025
2025-03-31
Q1 2025
2024-12-31
Q4 2024
Revenue$1.61B$1.6B$1.59B$1.54B$1.48B$1.46B$1.46B$1.41B
Gross Margin21.6%44.5%44.4%44%42.5%43%43.3%41.7%
Operating Margin17.9%18.1%19%18.3%16.5%17.8%18.3%16.5%
Net Income$149.9M$153.9M$194.5M$146.1M$126.5M$142.1M$151.5M$120.9M
Diluted EPS1.51.541.931.431.241.391.481.18
Operating Cash Flow$362M$282.6M$313.1M$346M$270.8M$270.2M$288.6M$278.8M

研究材料